Argent BioPharma

INNOVATIVE MULTIDISCIPLINARY DRUG DEVELOPMENT

Currently focused on the Central nervous system (CNS) and Immune Modulation for unmet medical needs

June 2024

Company Presentation

Disclaimer

The information contained in this presentation and any accompanying oral presentation ("Presentation") is being supplied to you by Argent BioPharma on behalf of itself and its subsidiaries (together, "Argent BioPharma "). By accepting this Presentation, you agree to be bound by the following terms.
The content of this Presentation has not been approved by an authorised person within the meaning of the Financial Services and Market Act 2000 (FSMA).
This Presentation is for background purposes only and is not intended to be relied upon as advice to investors or potential investors, and does not contain all information relevant or necessary for an investment decision. The Presentation should be read in conjunction with Argent BioPharma 's other periodic and continuous disclosure announcements filed with the Australian Securities Exchange. This Presentation does not constitute or form part of, and should not be construed as, an offer for sale or subscription of, or solicitation of any offer to buy or subscribe for, any securities of Argent BioPharma nor should it or any part of it form the basis of, or be relied on in connection with, or act as an inducement to enter into any contract or commitment whatsoever. The merits and suitability of any investment action in relation to securities should be considered carefully and involve, among other things, an assessment of the legal, tax, accounting, regulatory, financial, credit and other related aspects of such securities.
This Presentation is exempt from the general restriction set out in section 21 of FSMA on the communication of financial promotions.
This communication is exempt under the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the "Order") on the grounds that it is made or directed only to: (a) persons having professional experience in matters relating to investments within the definition of investment professionals in Article 19(5) of the Order; and (b) recipients who are high net worth bodies corporate, unincorporated associations, and partnerships and trustees of high value trusts as described in Article 49(2) of the Order; (all such persons together being referred to as "Relevant Persons"). Persons of any other description, including those that do not have professional experience in matters relating to investments, should not rely or act upon this Presentation, and the controlled investment and controlled activity to which this Presentation relates will only be available to Relevant Persons. If a person is unsure whether they would be classed as a Relevant Person, then they should seek independent legal advice or advice from an investment professional.
Not financial product advice
This document does not constitute financial product advice or take into account your investment objectives, taxation situation, financial situation or needs. This document consists of summarised information and does not involve or imply a recommendation of a statement of opinion in respect of whether to buy, sell or hold a financial product. An investment in Argent BioPharma is considered to be speculative in nature. Before making any investment decision in connection with any acquisition of securities, investors should consult their own legal, tax and/or financial advisers in relation to the information in, and action taken on the basis of, this document.
No Liability
The information contained in this Presentation has been prepared in good faith by Argent, however no guarantee, representation or warranty, expressed or implied is, or will be made, by any person (including Argent and its affiliates and their directors, officers, employees, associates, advisers and agents) as to the accuracy, reliability, correctness, completeness or adequacy of any statements, estimates, options, conclusions or other information contained in this document. To the maximum extent permitted by law, Argent BioPharma and its affiliates and their directors, officers, employees, associates, advisers and agents each expressly disclaims any and all liability, including, without limitation, any liability arising out of fault or negligence, for any loss arising from the use of or reliance on information contained in this document including representations or warranties or in relation to the accuracy or completeness of the information, statements, opinions, forecasts, reports or other matters, express or implied, contained in, arising out of or derived from, or for omissions from, this document including, without limitation, any financial information, any estimates or projections and any other financial information derived therefrom. Statements in this document are made only as of the date of this document unless otherwise stated and the information in this document remains subject to change without notice.
Argent BioPharma , nor its related bodies corporate, officers, their advisers, agents and employees accept any responsibility or liability to you or to any other person or entity arising out of this Presentation including pursuant to the general law (whether for negligence, under statute or otherwise), pursuant to the general law (whether for negligence, under statute or otherwise), or under the Australian Securities and Investments Commission Act 2001, Corporations Act 2001, Competition and Consumer Act 2010 or any corresponding provision of any Australian state or territory legislation (or the law of any similar legislation in any other jurisdiction), or similar provision under any applicable law. Any such responsibility or liability is, to the maximum extent permitted by law, expressly disclaimed and excluded.
Forward looking statements
The information in this presentation is for general information only. To the extent that certain statements contained in this presentation may constitute "forward-looking statements" or statements about "future matters", the information reflects Argent BioPharma 's intent, belief or expectations at the date of this presentation. In some cases forward looking statements can be identified by the use of terms such as "believes", "estimates", "anticipates", "projects", "expects", "intends", "may", "will", "seeks" or "should" or variations thereof, or by discussions of strategy, plans, objectives, goals, future events or intentions. Subject to any continuing obligations under applicable law or any relevant listing rules of the Australian Securities Exchange, Argent BioPharma disclaims any obligation or undertaking to provide you with access to any additional information or to update this Presentation or to correct any inaccuracies in, or omissions from this presentation which may become apparent.
Any forward-looking statements, including projections, guidance on future revenues, earnings and estimates, are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Argent BioPharma 's actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements. Any opinions, projections, estimates or forecasts contained in the Presentation constitute a judgment of Argent BioPharma only and should not be relied upon, and are provided as at the date of this Presentation and are subject to change without notice. This information is subject to change without notice. The accuracy of such information is not guaranteed, it may be incomplete or condensed and it may not contain all material information concerning Argent BioPharma and its subsidiaries. The forward-looking information contained in the Presentation is expressly qualified by this cautionary statement.
This Presentation must not be distributed, published, reproduced or otherwise made available to any person, in whole or in part, for any purposes whatsoever with addresses the United States, its territories or possessions or in any other jurisdiction outside of Australia or the United Kingdom where such distribution or availability may lead to a breach of any law or regulatory requirements. The distribution of this Presentation in other jurisdictions may be restricted by law, and persons into whose possession this Presentation come should inform themselves about, and observe, any such restrictions. Any failure to comply with these restrictions may constitute a violation of the laws of the relevant jurisdiction and you undertake to indemnify Argent for any loss or damage incurred as a result of your breach of this undertaking.

Clinical-Stage, Revenue Generating Biopharmaceutical Company committed to provide accessible medical treatments for unmet medical needs

We leverage nanotechnology and multidisciplinary drug development strategies to create multi-target therapies, focusing on central nervous system ("CNS") disorders and immune modulation.

Revenues Generating

Clinical stage biotechnology Company with **two** lead Phase 2 Investigational Medicinal Products (IMP) , introduced to market through early patient access schemes in the UK, USA, Europe, and Australia.

Integrated R&D and IMP Facilities

European research hub serving as an innovation center, nurturing new ideas into medical treatments and supporting the drug development lifecycle from concept to commercial launch.

To date, **over £30m has been invested** in Argent's research program.

Leveraging Real-World Data

Provision of treatments through early access schemes, yielding real-world data on safety and efficacy, supporting clinical trials.

Manufacturing Sites

Two EU GMP certified operational sites :

1. Produces medicinal products for clinical trials and early patient access schemes.
2. Fully commercial manufacturing facility for large-scale production of approved drugs, adhering to EU GMP and GDP guidelines.

Highly Experienced Argent BioPharma Management Team

Qualified team with versatile industry experience and expertise

Roby Zomer

Managing Director

Over 10 years of experience in the BioTech and AgroTech sectors alongside running large scale projects, bringing his extensive business contacts, scientific and engineering.

Yifat Steuer

Chief Operating Officer

A well-versed C-level with more than 20 years of experience specialise in scale up build to grow and build to sell. A chartered accountant with Deloitte.

Igor Bluvstein

Chief Financial Officer

Over 16 years of CFO roles and financial leadership. An extensive experience in NASDAQ, LSE, AIM listed companies. A chartered accountant with E&Y.

Amir Polak

Chief Pharmaceutical Development Officer

Over 20 years of experience in the pharma / Chemical industry, managing R&D work streams from concept to production. Amir holds an MSC in organic chemistry.

Sabina Suljaković

Chief Quality and Commercial Officer

An EU-registered Qualified Person, Responsible Person, and a Pharmacist, who brings over 10 years of experience in the pharmaceutical quality, manufacturing, and regulatory fields.

Yair Tal

Chief Information Security Officer

Over 10 years of experience in security management, data protection, and physical cyber security, from the company's facilities to its online operations and most significantly, patient data.



Key Products

CannEpil®

Refractory Epilepsy

Revenue Generating Refractory Epilepsy Seizure Control

- Approximately 30% of generalized seizure epilepsy patients have Refractory Epilepsy aka “Drug-Resistant Epilepsy" (DRE)[1]
- CannEpil® is now available to patients in the UK by **Named Patient Request**, to be prescribed by clinicians in the UK who are listed on the **GMC Specialist** Register.
- CannEpil® accepted by the Irish Health Product Regulatory Authority (HPRA) and obtaining **full health insurance coverage** by LTI or GMS scheme.
- The first UK patient has access to CannEpil® through the NHS **RESCAS** pathway and “**I am Billy Foundation**”
- Accepted by first European country and fully covered under the Primary Care Reimbursement Service[2]
- Results of Preclinical and Clinical program to date shows:
  - Positive safety assessments
  - Safety study completed — CannEpil® was found to be safe for post-treatment driving activities[3]
  - Positive results for a head-to-head clinical study on 100 patients comparing CannEpil® to a CBD only formulation[4]

Epilepsy Therapeutics Worldwide Market £15B[5] by 2030

1. Fattorusso A, et al. (2021) The Pharmacoresistant Epilepsy: An Overview on Existent and New Emerging Therapies. Front. Neurol.
2. https://www2.hse.ie/services/schemes-allowances/medical-cannabis-products-reimbursement-scheme/ ASX
3. Date on file – CannEpil Driving Performance
4. Data on file – CannEpil vs. MXP100 study
5. https://www.biospace.com/article/epilepsy-therapeutics-market-worth-15-1-bn-by-2030-at-a-cagr-of-4-5-percent-/

CannEpil®

Refractory Epilepsy

Market Potential

Worldwide Patients with DRE	UK Potential Patients with DRE	CannEpil Treatment Estimate, Per Patient Per Annum
15M	150K	£7,000[3]

Key Points

- There are 50[1] million epilepsy sufferers of which 6.21 million in Europe and the UK
- Approximately 30% of generalized seizure epilepsy patients have Refractory Epilepsy aka “Drug-Resistant Epilepsy" (DRE)[2]
- CannEpil® already sold in the UK, Ireland and Australia
- CannEpil® commercial strategy is a combination of 3rd party distribution supported by in-house Medical Scientific Liaison
- Key wholesaler partners in the UK and Europe: PCCA and Medicinal

Forwards Looking (2024–25)

- Continuing the work with the ‘I am Billy’ Foundation and the pathway to NHS RESCAS for Paediatric Refractory Epilepsy
- Dedicated Neurology and Paediatrician collaboration with the European Paediatric Neurology Society[4] in-house
- Initiate CannEpil® IND submission to the US FDA

1. https://www.who.int/news-room/fact-sheets/detail/epilepsy Fattorusso A, et al. (2021) The Pharmacoresistant Epilepsy
2. Overview on Existant and New Emerging Therapies. Front. Neurol. 12:674483.
3. Alacrita Report 2019
4. http://dpnsee.org/2019/01/22/treatment-with-medicines-derived-from-cannabis/

CimetrA®

Acute Lung Injury
and ARDS

Argent BioPharma

Revenue Generating Immunomodulation Treatment for Acute Lung Injury ('ALI') and Acute Respiratory Distress Syndrome ('ARDS')

CimetrA® has now been listed under the ArtemiC™ label as an over-the-counter (OTC) unlicenced drug non-prescription in the USA, following the listing on the FDA National Drug Code Database (NDC).
CimetrA® delivered 50,000 units to the USA market (Under Special Access)

Results of Preclinical and Clinical program, meeting FDA guidelines, to date:

- Demonstrated suppression of cytokine storm in COVID-19 patients in Clinical Trials[1]
- Demonstrated reduction in C-reactive protein (CRP), a major inflammatory marker in COVID-19[2].
- The biological markers in the blood tests support the claim of a reduction of inflammation and enterohepatic involvement, as well as liver reactant proteins[1].
- Preclinical study in both rodent (rats, mice) and non-rodent (swine) confirming safety profile, with no formulation-related toxicity detected[3].
- Preclinical studies elucidating its mechanism of action particularly its efficacy in downregulating cytokine responses upon immune stimulation in human peripheral blood mononuclear cells (PBMCs)[1]
- Effective blocking of the IL-32mRNA expression1, the pro-inflammatory cytokine related to Autoimmune diseases, lupus, rheumatoid arthritis, inflammatory bowel disease, asthma, and chronic obstructive pulmonary disease[1]

Worldwide Market
ALI & ARDS
£7.3B [4 5]
By c.2030

1. Data on file – CimetrA in-vitro study
2. Data on file – Interim results – CimetrA Dose Finding Study
3. Data on file – CimetrA pre-clinical study
4. ARDS https://www.mordorintelligence.com/industry-reports/acute-respiratory-distress-syndrome-treatment-market
5. Acute Lung Injury https://www.transparencymarketresearch.com/acute-lung-injury-treatment-market.html#:~:text=The%20global%20market%20was%20valued%20at%20US%24%203.0%20Bn%20in%202021.

CimetrA®

Acute Lung Injury and ARDS

Market Potential

Cases of severe illness of influenza worldwide[1] **3–5M** per annum

Respiratory deaths[1] **290–650K** per annum

Potentially, CimetrA® can be used to treat **inflammatory** conditions with **£100B**[2] total addressable market

Key Points

- Sales strategy is to license and distribute through 3rd party distribution supported by in-house Medical Scientific Liaison
- Key wholesaler partners in the USA and MENA — AMC
- Initiate CimetrA® IND submission to the US FDA

Forwards Looking (2024–25)

CimetrA® IND submission to the US FDA

1. https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal)
2. https://www.precedenceresearch.com/anti-inflammatory-therapeutics-market

CogniCann®

Dementia
and Alzheimer's

Dementia and Alzheimer's

Designed as a treatment for the symptoms associated with Dementia and Alzheimer's

The safety and efficacy were assessed in a Phase II study in Australia

Patients in the Placebo group experienced a deterioration in their condition, compared with the stable neuropsychiatric profile of those patients in the treatment group with CogniCann®

Patients' aggressive behavior improved by 13%, compared with the Placebo Group, which improved by 4%

This important finding indicates not only improvement in the health status of the patients but also the improved quality of life of the families and caregivers taking care of dementia patients

Oromucosal Spray
Pharmaceutical Dosage Form

Data on file : CogniCann Phase II study, Australia
https://www.investi.com.au/api/announcements/mxc/7b107f7c-7be.pdf

IrniCan®

Glioblastoma

Glioblastoma

The Glioblastoma pre-clinical research, conducted between 2019-2022

The study demonstrated that IrniCan® was cytotoxic to Glioblastoma tumor and stem cells, reducing the cells' viability and inducing caspase-dependent cell apoptosis (or cell death).

Argent Pharma is planning to undertake additional research to further demonstrate the formulation's efficacy as a treatment for Glioblastoma.



1. Lah, T. . et al. The Cytotoxic Effects of Cannabidiol and Cannabigerol on Glioblastoma Stem Cells May Mostly Involve GPR55 and TRPV1 Signalling. Cancers 2022, 14, 5918T

Tablets
Pharmaceutical Dosage Form

Research and Development Product Pipeline

US FDA & EMA registration

European Medicines Agency (EMA) & the United States of America (USA) Food and Drug Administration (FDA)



R&D Centres and Manufacturing Capabilities

R&D Centers and Manufacturing Capabilities

Integrated research hub

- Support the company's current and future R&D activities
- Currently manages and runs clinical trials both in-house* and with third-party CROs
- Opportunity for third party revenue generation

Fully built GMP pharma standard manufacturing facility

- Two, high-quality, European production facilities to manufacture and distribute Argent's proprietary IMP products CannEpil®, CimetrA®, and CogniCann®
- Slovenia production facility EU-GMP since 2018, Malta production facility EU-GMP since 2023
- 80% government-funded Malta production facility was EU-GMP certification in April 2023
- Support the company's current and future manufacturing activities

*In accordance with the European Medicines Agency, Federal Drug Administration, ICH Good Clinical Practice, and Israeli health regulations

Argent BioPharma

Addresses unmet medical needs